Department of Urology, Handan First Hospital, Handan, China.
Department of General Surgery, Handan First Hospital, Handan, China.
Front Endocrinol (Lausanne). 2023 Apr 21;14:1131564. doi: 10.3389/fendo.2023.1131564. eCollection 2023.
There is no consensus on whether intravenous rehydration must be added after preoperative phenoxybenzamine (PXB) administration for pheochromocytoma. The aim of this study is to investigate whether abandonment of intravenous volume expansion after PXB administration is associated with intraoperative hemodynamic instability.
83 Patients with pheochromocytoma received surgical treatment in the Department of Urology, Handan First Hospital, between October 2014 and July 2022. All patients were subclassified into either the hemodynamic stability group (HS group) or the hemodynamic instability group (HU group) according to whether intraoperative hemodynamic instability occurred, with 51 cases in HS group and 32 cases in HU group. Differences in data between the two groups were examined, and the risk factors for intraoperative hemodynamic instability were analyzed using logistic regression.
The results of the analysis showed no statistically significant differences in age, sex, location of the tumor, surgical method, body mass index (BMI) ≥ 24 kg/m, blood and urine catecholamine test results, preoperative oral PXB followed by combined intravenous volume expansion, proportion of patients with hypertension or diabetes mellitus or coronary heart disease between the two groups (P>0.05). The size of the tumor in the HS group was smaller than that in the HU group (5.3 ± 1.9 cm vs 6.2 ± 2.4 cm P=0.010). Multivariate analyses demonstrated that abandonment of intravenous volume expansion after preoperative receipt of α-blockers in patients with adrenal pheochromocytoma was not an independent risk factor for intraoperative hemodynamic instability. Only the tumor size (P=0.025) was an independent risk factor for intraoperative hemodynamic instability.
The purpose of general preoperative intravenous fluid expansion is to prevent hypotension after the tumor has been resected. In the current study, we indicated that preoperative management of pheochromocytomas using the α-blocker PXB in combination with intravenous volume expansion does not further reduce the risk of intraoperative hemodynamic instability or postoperative complications compared with oral PXB alone. Therefore, our study supports preoperative management of pheochromocytoma with a single α-blocker, PXB, as sufficient.
对于嗜铬细胞瘤,在使用苯氧苄胺(PXB)术前是否必须补充静脉补液目前尚无共识。本研究旨在探讨在使用 PXB 后是否放弃静脉容量扩张是否与术中血流动力学不稳定相关。
2014 年 10 月至 2022 年 7 月,我院泌尿科收治的 83 例嗜铬细胞瘤患者,根据术中是否出现血流动力学不稳定分为血流动力学稳定组(HS 组)和血流动力学不稳定组(HU 组),其中 HS 组 51 例,HU 组 32 例。比较两组患者数据差异,采用 logistic 回归分析术中血流动力学不稳定的危险因素。
分析结果显示,两组患者在年龄、性别、肿瘤部位、手术方式、体质指数(BMI)≥24kg/m、血、尿儿茶酚胺检测结果、术前口服 PXB 联合静脉容量扩张、高血压、糖尿病、冠心病患者比例等方面差异无统计学意义(P>0.05)。HS 组肿瘤直径小于 HU 组(5.3±1.9cm vs 6.2±2.4cm,P=0.010)。多因素分析表明,肾上腺嗜铬细胞瘤患者术前接受α受体阻滞剂治疗后放弃静脉补液不是术中血流动力学不稳定的独立危险因素。只有肿瘤大小(P=0.025)是术中血流动力学不稳定的独立危险因素。
一般术前静脉补液的目的是预防肿瘤切除后低血压。在本研究中,我们发现与单独口服 PXB 相比,术前使用 PXB 联合静脉容量扩张治疗嗜铬细胞瘤并不能进一步降低术中血流动力学不稳定或术后并发症的风险。因此,我们的研究支持术前使用单一α受体阻滞剂 PXB 治疗嗜铬细胞瘤。